Kymble Spriggs, Marsus Pumar, Elizabeth Leahy, Nicole Weibel, Sara Barnes
{"title":"杰克跳蚁毒液过敏患者的健康相关生活质量:毒液过敏生活质量问卷 \"VQLQ的验证。","authors":"Kymble Spriggs, Marsus Pumar, Elizabeth Leahy, Nicole Weibel, Sara Barnes","doi":"10.1016/j.jaip.2024.11.009","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We assessed health-related quality of life (HRQoL) in patients with allergy to the venom of the jack jumper ant (JJA), Myrmecia pilosula, a Hymenoptera order species native and endemic to the Southeastern quarter of Australia. To our knowledge, this has not previously been studied despite an estimated population prevalence of generalized allergic symptoms as high as 3% in some areas.</p><p><strong>Objective: </strong>To validate the Venom Quality of Life Questionnaire (VQLQ) HRQoL instrument, which was previously validated in patients with wasp and bee venom allergy, for use in this specific ant venom-allergic population.</p><p><strong>Methods: </strong>The 14-item VQLQ survey instrument was administered to patients with clinical allergy to JJA venom presenting at the state treatment center for venom immunotherapy. Surveys were performed at different time points of the progression through visits for venom immunotherapy treatment. We performed cross-sectional and longitudinal validation against the Expectation of Outcome (EO) questionnaire by determining correlations and agreement.</p><p><strong>Results: </strong>A total of 271 individuals contributed survey data, median age 52 years (range, 3-85 years; bimodal distribution with 25% aged <18 years). Internal consistency was excellent (Cronbach α = 0.95). Cross-sectional validity was demonstrated with a positive correlation of VQLQ to EO of 0.44 (P < .001). Performance was nearly identical when stratified into adults and children (aged <18 years). Longitudinal validity was suggested as both VQLQ and EO improved over time in both adults and children, but this had paired correlation at only two time points in adults. Bland-Altman analysis demonstrated acceptable agreement between VQLQ and EO and no evidence of systematic bias.</p><p><strong>Conclusions: </strong>The VQLQ appears to offer performance of HRQoL measurement in patients with JJA venom allergy, similar to that previously demonstrated in other Hymenoptera species. In addition, this study demonstrates cross-sectional validity specifically in a pediatric population aged 3 to 18 years.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":"89-94"},"PeriodicalIF":8.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Health-Related Quality of Life in Jack Jumper Ant Venom Allergy: Validation of the Venom-Allergy Quality of Life Questionnaire.\",\"authors\":\"Kymble Spriggs, Marsus Pumar, Elizabeth Leahy, Nicole Weibel, Sara Barnes\",\"doi\":\"10.1016/j.jaip.2024.11.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>We assessed health-related quality of life (HRQoL) in patients with allergy to the venom of the jack jumper ant (JJA), Myrmecia pilosula, a Hymenoptera order species native and endemic to the Southeastern quarter of Australia. To our knowledge, this has not previously been studied despite an estimated population prevalence of generalized allergic symptoms as high as 3% in some areas.</p><p><strong>Objective: </strong>To validate the Venom Quality of Life Questionnaire (VQLQ) HRQoL instrument, which was previously validated in patients with wasp and bee venom allergy, for use in this specific ant venom-allergic population.</p><p><strong>Methods: </strong>The 14-item VQLQ survey instrument was administered to patients with clinical allergy to JJA venom presenting at the state treatment center for venom immunotherapy. Surveys were performed at different time points of the progression through visits for venom immunotherapy treatment. We performed cross-sectional and longitudinal validation against the Expectation of Outcome (EO) questionnaire by determining correlations and agreement.</p><p><strong>Results: </strong>A total of 271 individuals contributed survey data, median age 52 years (range, 3-85 years; bimodal distribution with 25% aged <18 years). Internal consistency was excellent (Cronbach α = 0.95). Cross-sectional validity was demonstrated with a positive correlation of VQLQ to EO of 0.44 (P < .001). Performance was nearly identical when stratified into adults and children (aged <18 years). Longitudinal validity was suggested as both VQLQ and EO improved over time in both adults and children, but this had paired correlation at only two time points in adults. Bland-Altman analysis demonstrated acceptable agreement between VQLQ and EO and no evidence of systematic bias.</p><p><strong>Conclusions: </strong>The VQLQ appears to offer performance of HRQoL measurement in patients with JJA venom allergy, similar to that previously demonstrated in other Hymenoptera species. In addition, this study demonstrates cross-sectional validity specifically in a pediatric population aged 3 to 18 years.</p>\",\"PeriodicalId\":51323,\"journal\":{\"name\":\"Journal of Allergy and Clinical Immunology-In Practice\",\"volume\":\" \",\"pages\":\"89-94\"},\"PeriodicalIF\":8.2000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Allergy and Clinical Immunology-In Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jaip.2024.11.009\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology-In Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaip.2024.11.009","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
Health-Related Quality of Life in Jack Jumper Ant Venom Allergy: Validation of the Venom-Allergy Quality of Life Questionnaire.
Background: We assessed health-related quality of life (HRQoL) in patients with allergy to the venom of the jack jumper ant (JJA), Myrmecia pilosula, a Hymenoptera order species native and endemic to the Southeastern quarter of Australia. To our knowledge, this has not previously been studied despite an estimated population prevalence of generalized allergic symptoms as high as 3% in some areas.
Objective: To validate the Venom Quality of Life Questionnaire (VQLQ) HRQoL instrument, which was previously validated in patients with wasp and bee venom allergy, for use in this specific ant venom-allergic population.
Methods: The 14-item VQLQ survey instrument was administered to patients with clinical allergy to JJA venom presenting at the state treatment center for venom immunotherapy. Surveys were performed at different time points of the progression through visits for venom immunotherapy treatment. We performed cross-sectional and longitudinal validation against the Expectation of Outcome (EO) questionnaire by determining correlations and agreement.
Results: A total of 271 individuals contributed survey data, median age 52 years (range, 3-85 years; bimodal distribution with 25% aged <18 years). Internal consistency was excellent (Cronbach α = 0.95). Cross-sectional validity was demonstrated with a positive correlation of VQLQ to EO of 0.44 (P < .001). Performance was nearly identical when stratified into adults and children (aged <18 years). Longitudinal validity was suggested as both VQLQ and EO improved over time in both adults and children, but this had paired correlation at only two time points in adults. Bland-Altman analysis demonstrated acceptable agreement between VQLQ and EO and no evidence of systematic bias.
Conclusions: The VQLQ appears to offer performance of HRQoL measurement in patients with JJA venom allergy, similar to that previously demonstrated in other Hymenoptera species. In addition, this study demonstrates cross-sectional validity specifically in a pediatric population aged 3 to 18 years.
期刊介绍:
JACI: In Practice is an official publication of the American Academy of Allergy, Asthma & Immunology (AAAAI). It is a companion title to The Journal of Allergy and Clinical Immunology, and it aims to provide timely clinical papers, case reports, and management recommendations to clinical allergists and other physicians dealing with allergic and immunologic diseases in their practice. The mission of JACI: In Practice is to offer valid and impactful information that supports evidence-based clinical decisions in the diagnosis and management of asthma, allergies, immunologic conditions, and related diseases.
This journal publishes articles on various conditions treated by allergist-immunologists, including food allergy, respiratory disorders (such as asthma, rhinitis, nasal polyps, sinusitis, cough, ABPA, and hypersensitivity pneumonitis), drug allergy, insect sting allergy, anaphylaxis, dermatologic disorders (such as atopic dermatitis, contact dermatitis, urticaria, angioedema, and HAE), immunodeficiency, autoinflammatory syndromes, eosinophilic disorders, and mast cell disorders.
The focus of the journal is on providing cutting-edge clinical information that practitioners can use in their everyday practice or to acquire new knowledge and skills for the benefit of their patients. However, mechanistic or translational studies without immediate or near future clinical relevance, as well as animal studies, are not within the scope of the journal.